Themis Medicare Limited (THEMISMED) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Themis Medicare Limited (THEMISMED) has a cash flow conversion efficiency ratio of -0.004x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Rs-14.84 Million ≈ $-160.49K USD) by net assets (Rs3.80 Billion ≈ $41.10 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Themis Medicare Limited liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Themis Medicare Limited - Cash Flow Conversion Efficiency Trend (2006–2025)
This chart illustrates how Themis Medicare Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Themis Medicare Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Themis Medicare Limited ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Samil Pharm
KO:000520
|
0.016x |
|
Nordhealth AS
OL:NORDH
|
-0.008x |
|
New Delhi Television Limited
NSE:NDTV
|
1.199x |
|
Netas Telekomunikasyon AS
IS:NETAS
|
0.222x |
|
Oroco Resource Corp
V:OCO
|
-0.014x |
|
Spheria Emerging Companies Ltd
AU:SEC
|
0.041x |
|
Alpha Astika Akinita S.A
AT:ASTAK
|
-0.330x |
|
Novus Holdings Ltd
JSE:NVS
|
0.038x |
Annual Cash Flow Conversion Efficiency for Themis Medicare Limited (2006–2025)
The table below shows the annual cash flow conversion efficiency of Themis Medicare Limited from 2006 to 2025. For the full company profile with market capitalisation and key ratios, see how much is Themis Medicare Limited worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | Rs4.03 Billion ≈ $43.54 Million |
Rs347.10 Million ≈ $3.75 Million |
0.086x | +47.37% |
| 2024-03-31 | Rs3.78 Billion ≈ $40.84 Million |
Rs220.94 Million ≈ $2.39 Million |
0.059x | +23.40% |
| 2023-03-31 | Rs3.39 Billion ≈ $36.71 Million |
Rs160.93 Million ≈ $1.74 Million |
0.047x | -60.37% |
| 2022-03-31 | Rs2.87 Billion ≈ $31.09 Million |
Rs343.94 Million ≈ $3.72 Million |
0.120x | -54.12% |
| 2021-03-31 | Rs2.19 Billion ≈ $23.63 Million |
Rs569.75 Million ≈ $6.16 Million |
0.261x | +14440.88% |
| 2020-03-31 | Rs1.83 Billion ≈ $19.79 Million |
Rs3.28 Million ≈ $35.49K |
0.002x | -97.41% |
| 2019-03-31 | Rs1.58 Billion ≈ $17.09 Million |
Rs109.23 Million ≈ $1.18 Million |
0.069x | +48.70% |
| 2018-03-31 | Rs1.69 Billion ≈ $18.26 Million |
Rs78.47 Million ≈ $848.62K |
0.046x | +152.43% |
| 2017-03-31 | Rs1.20 Billion ≈ $13.03 Million |
Rs-106.78 Million ≈ $-1.15 Million |
-0.089x | -128.86% |
| 2016-03-31 | Rs788.89 Million ≈ $8.53 Million |
Rs242.32 Million ≈ $2.62 Million |
0.307x | +0.33% |
| 2015-03-31 | Rs589.08 Million ≈ $6.37 Million |
Rs180.34 Million ≈ $1.95 Million |
0.306x | +188.73% |
| 2014-03-31 | Rs561.85 Million ≈ $6.08 Million |
Rs59.57 Million ≈ $644.27K |
0.106x | +25.17% |
| 2013-03-31 | Rs537.17 Million ≈ $5.81 Million |
Rs45.51 Million ≈ $492.12K |
0.085x | +132.21% |
| 2012-03-31 | Rs580.79 Million ≈ $6.28 Million |
Rs-152.73 Million ≈ $-1.65 Million |
-0.263x | -639.73% |
| 2011-03-31 | Rs910.26 Million ≈ $9.84 Million |
Rs44.35 Million ≈ $479.64K |
0.049x | +16.28% |
| 2010-03-31 | Rs833.43 Million ≈ $9.01 Million |
Rs34.92 Million ≈ $377.67K |
0.042x | +145.22% |
| 2009-03-31 | Rs918.65 Million ≈ $9.93 Million |
Rs-85.13 Million ≈ $-920.63K |
-0.093x | -9.87% |
| 2008-03-31 | Rs845.93 Million ≈ $9.15 Million |
Rs-71.35 Million ≈ $-771.58K |
-0.084x | -184.24% |
| 2007-03-31 | Rs691.60 Million ≈ $7.48 Million |
Rs69.24 Million ≈ $748.82K |
0.100x | +155.05% |
| 2006-03-31 | Rs605.21 Million ≈ $6.55 Million |
Rs23.76 Million ≈ $256.92K |
0.039x | -- |
About Themis Medicare Limited
Themis Medicare Limited, together with its subsidiaries, manufactures and sells pharmaceutical products in India and internationally. It offers active pharmaceutical ingredients (APIs) and formulations used in various therapeutic areas, including anti-tuberculosis, analgesic and anti-inflammatory, analgesic and antispasmodic, analgesics, anesthesia, antacid-antiflatulent, anti-fungal, antibiotic,… Read more